Novavax's protein-based COVID vaccine induces broad functional immune response against XBB subvariants, data shows

Novavax, Inc., a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, today announced that its updated protein-based XBB COVID vaccine candidate induced neutralizing antibody responses to the EG.5.1 and XBB.1.16.6 subvariants in small animal and non-human primate studies.

Related Keywords

Lily Ramsey ,Filip Dubovsky ,Centers For Disease Control ,European Union ,Vaccination Program ,Novavax Inc ,Emergency Use Authorization ,Coronavirus Disease ,Acute Allergic Reactions ,Disease Control ,Vaccine Effectiveness ,Vaccine Adverse Event Reporting System ,Multisystem Inflammatory Syndrome ,Immune Response ,Protein ,Vaccine ,Anaphylaxis ,Ntibody ,Coronavirus ,Covid 19 ,Painting ,Myocarditis ,Rain ,Pericarditis ,Research ,Yndrome ,